Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Artesunate

Generic name
Artesunate
Brand name
ATC Code
P01BE03

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Severe tropical malaria (P. falciparum)
  • Intravenous
    • < 20 kg
      [1]
      • 3 mg/kg/dose at 0, 12 and 24 hours, then once daily..

      • Intravenous administration for at least 24 hours; after that a switch can be made to oral therapy.

    • ≥ 20 kg
      [1]
      • 2.4 mg/kg/dose at 0, 12 and 24 hours, then once daily..

      • Intravenous administration for at least 24 hours; after that a switch can be made to oral therapy.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Reversible blood count abnormalities: delayed or persistent haemolytic anemia (increased risk in hyperparasitemia and in young children (at 6 months–10 years; approx. 7%).

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Since haemolysis and anemia can still occur 14–28 days after treatment with artesunate, monitor the hemoglobin level for a further 4 weeks after treatment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Aminoquinolines
P01BA01
P01BA02
Biguanides
P01BB01
Methanolquinolines
P01BC02
P01BC01
Diaminopyrimidines
P01BD01
Artemisinin and derivatives, combinations
P01BF01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Reference

  1. WHO, Guidelines for the treatment of malaria., www.who.int, 2015, 3rd edition

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes